Citations (130)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Rajiv Jash, D. S. N. B. K. Prasanth, Moumita Jash & Achanti Suneetha. (2023) Small molecules in the race of COVID-19 drug development. Journal of Asian Natural Products Research 0:0, pages 1-22.
Read now
Read now
Mona Mosayebnia, Atefeh Hajiagha Bozorgi, Maliheh Rezaeianpour & Farzad Kobarfard. (2022) In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling. Journal of Biomolecular Structure and Dynamics 40:14, pages 6569-6586.
Read now
Read now
Thoraya A. Farghaly, Amani M. R. Alsaedi, Noof A. Alenazi & Marwa F. Harras. (2022) Anti-viral activity of thiazole derivatives: an updated patent review. Expert Opinion on Therapeutic Patents 32:7, pages 791-815.
Read now
Read now
Prateek Kumar, Taniya Bhardwaj, Ankur Kumar, Bhuvaneshwari R. Gehi, Shivani K. Kapuganti, Neha Garg, Gopal Nath & Rajanish Giri. (2022) Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study. Journal of Biomolecular Structure and Dynamics 40:7, pages 3170-3184.
Read now
Read now
Laith K Hasan, Brittney Deadwiler, Aryan Haratian, Ioanna K Bolia, Alexander E Weber & Frank A Petrigliano. (2021) Effects of COVID-19 on the Musculoskeletal System: Clinician’s Guide. Orthopedic Research and Reviews 13, pages 141-150.
Read now
Read now
Soha R Abd El Hadi, Esmat E Zien El-Deen, Mostafa M Bahaa, Abdelfattah A Sadakah & Heba A Yassin. (2021) COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach. Drug Design, Development and Therapy 15, pages 3313-3330.
Read now
Read now
Masoumeh Sadat Mousavi Maleki, Mosayeb Rostamian & Hamid Madanchi. (2021) Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2. Expert Review of Anti-infective Therapy 19:10, pages 1205-1217.
Read now
Read now
Ankit Jain, Shiv Kumar Prajapati, Madhavi Tripathi, Ashok M. Raichur & Jagat R. Kanwar. (2021) Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights. Expert Review of Clinical Pharmacology 14:6, pages 715-734.
Read now
Read now
Betsy Ann Joseph, Mahmoud Dibas, Kirk W. Evanson, Geeta Paranjape, Charan Thej Reddy Vegivinti, Pragadeesh Thamarai Selvan, Kavitha Saravu, Nitin Gupta, Yashwitha Sai Pulakurthi, Praneeth Reddy Keesari, Sriram Varsha, Spandana Chittajallu, Adam A. Dmytriw, Natalie L. Reierson, Nick Mikoff, Shelby Kamrowski, Megan Schmidt, Amber R. Davis, John M. Pederson, Hemant K. Mishra, Jillienne C. Touchette & Kevin Kallmes. (2021) Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review. Expert Review of Anti-infective Therapy 19:6, pages 679-687.
Read now
Read now
Radostina Alexandrova, Pencho Beykov, Dobrin Vassilev, Marko Jukić & Črtomir Podlipnik. (2021) The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. Biotechnology & Biotechnological Equipment 35:1, pages 74-102.
Read now
Read now
Fisayo A. Olotu, Clement Agoni, Opeyemi Soremekun & Mahmoud E. S. Soliman. (2020) The recent application of 3D-QSAR and docking studies to novel HIV-protease inhibitor drug discovery. Expert Opinion on Drug Discovery 15:9, pages 1095-1109.
Read now
Read now
Sujit Kumar Debnath, Rohit Srivastava & Abdelwahab Omri. (2020) Emerging therapeutics for the management of COVID 19. Expert Opinion on Emerging Drugs 25:3, pages 337-351.
Read now
Read now
Mulatu Biru, Degu Jerene, Pia Lundqvist, Mitikie Molla, Workeabeba Abebe & Inger Hallström. (2017) Caregiver-reported antiretroviral therapy non-adherence during the first week and after a month of treatment initiation among children diagnosed with HIV in Ethiopia. AIDS Care 29:4, pages 436-440.
Read now
Read now
Baralee Punyawudho, Noppaket Singkham, Narukjaporn Thammajaruk, Theera Dalodom, Stephen J Kerr, David M Burger & Kiat Ruxrungtham. (2016) Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients. Expert Review of Clinical Pharmacology 9:12, pages 1583-1595.
Read now
Read now
Beatriz Larru Martinez & F Andrew I Riordan. (2010) Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children. HIV/AIDS - Research and Palliative Care 2, pages 59-67.
Read now
Read now
P. Annaert, Z.W. Ye, B. Stieger & P. Augustijns. (2010) Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:3, pages 163-176.
Read now
Read now
Articles from other publishers (114)
Papisetti venkatesham, Dominique Schols, Leentje Persoons, Sandra Claes, Akanksha Ashok Sangolkar, Raju Chedupaka & Rajeswar Rao Vedula. (2023) Synthesis of novel thioalkylated triazolothiazoles and their promising in-vitro antiviral activity. Journal of Molecular Structure 1286, pages 135573.
Crossref
Crossref
Zirui Zeng. (2023) Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives. Technology and Health Care 31, pages 169-184.
Crossref
Crossref
Hayat Ullah, Mehvish Jabeen, Fazal Rahim, Amjad Hussain, Fahad Khan, Muhammad Perviaz, Muhammad Sajid, Imad Uddin, Muhammad Usman Khan & Muhammad Nabi. (2023) Synthesis, acetylcholinesterase and butyrylcholinesterase inhibitory potential and molecular docking study of thiazole bearing thiourea analogues. Chemical Data Collections 44, pages 100988.
Crossref
Crossref
Jaeok Lee, Jihye Kim, Jiyeon Kang & Hwa Jeong Lee. (2022) COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Journal of Pharmaceutical Investigation 53:2, pages 191-212.
Crossref
Crossref
Rajeshwar Kamal Kant AryaNeeraj Kumar SethiyaDheeraj BishtMohmmad RashidDeepak Kumar, Anita SinghRupa GuptaVijay Singh Rana. (2023) An Overview on Chemical Features and Metabolism of Synthetic and Natural Product-Based Medicine for Combating COVID-19. Research Journal of Pharmacy and Technology, pages 908-916.
Crossref
Crossref
Arbind Kumar, Aashish Sharma, Narendra Vijay Tirpude, Sharad Thakur & Sanjay Kumar. (2023) Combating the Progression of Novel Coronavirus SARS-CoV-2
Infectious Disease: Current State and Future Prospects in
Molecular Diagnostics and Drug Discovery. Current Molecular Medicine 23:2, pages 127-146.
Crossref
Crossref
Lizette Gil-del-Valle, Rosario Gravier-Hernández, Waldemar Baldoquin-Rodríguez, Beatriz Sierra-Vázquez, Ana Beatriz Perez-Díaz, Pablo Sariol-Resik, Tatiana Prieto-Dominguez, Mario Manuel Delgado-Guerra, Joniel Arnoldo Sánchez- Márquez, Olga Elena López-Fernández, Faustina Fonseca-Betancourt, Liana Valdés-Lanza, Odalys Orraca-Castillo, Xaveer Van Ostade, Wim Vanden Berghe, Veerle Vanlerberghe & M. Guadalupe Guzmán-Tirado. (2023) Adverse Drug Reactions during COVID-19 Treatment: A Comprehensive Analysis Focused on Hospitalized Patients, with the Use of a Survey in Cuba in 2020. Advances in Pharmacological and Pharmaceutical Sciences 2023, pages 1-12.
Crossref
Crossref
Mahmoud Kandeel, Mohamed A. Morsy, Hany M. Abd El-Lateef, Mohamed Marzok, Hossam S. El-Beltagi, Khalid M. Al Khodair, Ibrahim Albokhadaim & Katharigatta N. Venugopala. (2023) The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients. Processes 11:2, pages 398.
Crossref
Crossref
Roshika Tyagi, Catherine Paul, Juni Banerjee, Rajeev Kaul & Shuvomoy Banerjee. (2022) Virus Association with Gastric Inflammation and Cancer: An Updated Overview. Journal of Medical Microbiology and Infectious Diseases 10:4, pages 163-178.
Crossref
Crossref
Vyoma Snehal Trivedi, Albert Frank Magnusen, Reena Rani, Luca Marsili, Anne Michele Slavotinek, Daniel Ray Prows, Robert James Hopkin, Mary Ashley McKay & Manoj Kumar Pandey. (2022) Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. International Journal of Molecular Sciences 23:22, pages 14340.
Crossref
Crossref
Putu Prathiwi Primadharsini, Shigeo Nagashima, Masaharu Takahashi, Kazumoto Murata & Hiroaki Okamoto. (2022) Ritonavir Blocks Hepatitis E Virus Internalization and Clears Hepatitis E Virus In Vitro with Ribavirin. Viruses 14:11, pages 2440.
Crossref
Crossref
Lucas Barboza Moreira Pinheiro, Songsheng Tao, Elizabeth Culbertson, Gabriel Lima Barros de Araujo, Simon J.L. Billinge & Fabio Furlan Ferreira. (2022) Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems. International Journal of Pharmaceutics 628, pages 122329.
Crossref
Crossref
Rajesh Basnet, Sandhya Khadka, Buddha Bahadur Basnet, Til Bahadur Basnet & Sanjeep Sapkota. (2022) Overview of Drug Therapy of COVID-19 with Safety and the Potential
Clinical Benefits. Current Drug Therapy 17:5, pages 327-333.
Crossref
Crossref
Livia Roseti & Brunella Grigolo. (2022) COVID-19 and rheumatic diseases: A mini-review. Frontiers in Medicine 9.
Crossref
Crossref
Namy George, Mohd. Imran, Shah Alam Khan, Khalid Al Balushi, Syed Mohammed Basheeruddin Asdaq & Shahamah Jomah. (2022) A Spotlight on the Development, Pharmaceutical Trends, Innovations and Patents of Nirmatrelvir (PaxlovidTM). International Journal of Pharmacology 18:7, pages 1340-1352.
Crossref
Crossref
Ashley Jia Wen Yip, Zheng Yao Low, Vincent T. K. Chow & Sunil K. Lal. (2022) Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity. Viruses 14:6, pages 1345.
Crossref
Crossref
Carlos K. H. Wong, Marshall C. H. Low, Ashley C. Y. Kwok, Angel Y. C. Lui, Kristy T. K. Lau, Ivan C. H. Au, Xi Xiong, Matthew S. H. Chung, Mike Y. W. Kwan, Eric H. Y. Lau & Benjamin J. Cowling. (2022) Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study. Pediatric Drugs 24:3, pages 269-280.
Crossref
Crossref
Victor O. Ukwenya, Sunday A. Adelakun, Temiloluwa A. Fuwape & Ayotunde S. Adeagbo. (2022) The Impact of Deranged Glucose Metabolism and Diabetes in the Pathogenesis
and Prognosis of the Novel SARS-CoV-2: A Systematic Review of Literature. Current Diabetes Reviews 18:3.
Crossref
Crossref
Smitha Sammith ShettyVignesh KamathShibani ShettySwapna Bettanapalya VenkateshShrivardhan Kalghatgi. (2022) An Overview on Treatment Strategies by Allopathic and Alternative Forms of Medicines in Management of COVID -19. Research Journal of Pharmacy and Technology, pages 935-940.
Crossref
Crossref
Alina Tanase, Aniko Manea, Alexandra Denisa Scurtu, Lavinia Melania Bratu, Doina Chioran, Alina Dolghi, Iren Alexoi, Hazzaa AAbed, Voichita Lazureanu & Cristina Adriana Dehelean. (2022) The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment. Medicina 58:2, pages 261.
Crossref
Crossref
Mehdi Rasouli, Fatemeh Vakilian & Javad Ranjbari. (2022) Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical
Agents and Current Vaccines Against COVID-19. Current Stem Cell Research & Therapy 17:2, pages 166-185.
Crossref
Crossref
Farzaneh Sorouri, Zahra Emamgholipour, Maryam Keykhaee, Alireza Najafi, Loghman Firoozpour, Omid Sabzevari, Mohammad Sharifzadeh, Alireza Foroumadi & Mehdi Khoobi. (2022) The Situation of Small Molecules Targeting Key Proteins in combatting
SARS-CoV-2: Synthesis, Metabolic Pathway, Mechanism of Action, and
Potential Therapeutic Applications. Mini-Reviews in Medicinal Chemistry 22:2, pages 273-311.
Crossref
Crossref
Muhammad Naeem, Saba Manzoor, Mashhud-Ul-Hasan Abid, Muhammad Burhan Khan Tareen, Mirza Asad, Sajida Mushtaq, Nazia Ehsan, Dua Amna, Baojun Xu & Abu Hazafa. (2022) Fungal Proteases as Emerging Biocatalysts to Meet the Current Challenges and Recent Developments in Biomedical Therapies: An Updated Review. Journal of Fungi 8:2, pages 109.
Crossref
Crossref
Mahwish Akhtar, Noor Jahan, Muhammad Imran, Salman Ashfaq Ahmad, Sara Naqvi & Syed Muhammad Huzaifa Shah. (2022) Development of Potent SARS-CoV 3CL Protease Inhibitors: In silico Analogues
Designing of Darunavir, Molecular Modelling and Molecular Dynamic Simulation. Asian Journal of Chemistry 34:9, pages 2343-2350.
Crossref
Crossref
Noha Samir Taibe, Maimona A. Kord, Mohamed Ahmed Badawy, Iart Luca Shytaj & Mahmoud M. Elhefnawi. (2022) Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. Therapeutic Advances in Respiratory Disease 16, pages 175346662211327.
Crossref
Crossref
Judith M. White, Joshua T. Schiffer, Rachel A. Bender Ignacio, Shuang Xu, Denis Kainov, Aleksandr Ianevski, Tero Aittokallio, Matthew Frieman, Gene G. Olinger & Stephen J. Polyak. (2021) Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio 12:6.
Crossref
Crossref
Wei Yu, Xiaomin Wu, Yizhen Zhao, Chun Chen, Zhiwei Yang, Xiaochun Zhang, Jiayi Ren, Yueming Wang, Changwen Wu, Chengming Li, Rongfeng Chen, Xiaoli Wang, Weihong Zheng, Huaxin Liao & Xiaohui Yuan. (2021) Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules 26:23, pages 7385.
Crossref
Crossref
Nour K. Younis, Rana O. Zareef, Ghina Fakhri, Fadi Bitar, Ali H. Eid & Mariam Arabi. (2021) COVID-19: potential therapeutics for pediatric patients. Pharmacological Reports 73:6, pages 1520-1538.
Crossref
Crossref
Nurliana Abd MutalibMohd Amirul Ariffin Mohd RafiNormala Abd Latip. (2021) Revisiting CYP2C9-Mediated drug-drug Interactions: A Review. Research Journal of Pharmacy and Technology, pages 6166-6172.
Crossref
Crossref
Bilal Ahmad, Maria Batool, Qurat ul Ain, Moon Suk Kim & Sangdun Choi. (2021) Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International Journal of Molecular Sciences 22:17, pages 9124.
Crossref
Crossref
Bo Zhao, Teng-Fei Yang & Rui Zheng. (2021) Theory and reality of antivirals against SARS-CoV-2. World Journal of Clinical Cases 9:23, pages 6663-6673.
Crossref
Crossref
Swati Pawar, Kapil Kumar, Manish K. Gupta & Ravindra K. Rawal. (2021) Synthetic and Medicinal Perspective of Fused-Thiazoles as Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry 21:11, pages 1379-1402.
Crossref
Crossref
Ryan Ivone, Ashvin Fernando, Brenton DeBoef, Samantha A. Meenach & Jie Shen. (2021) Development of Spray-Dried Cyclodextrin-Based Pediatric Anti-HIV Formulations. AAPS PharmSciTech 22:5.
Crossref
Crossref
Safaet Alam, Taslima Binte Kamal, Md. Moklesur Rahman Sarker, Jin-Rong Zhou, S. M. Abdur Rahman & Isa Naina Mohamed. (2021) Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. Frontiers in Pharmacology 12.
Crossref
Crossref
Safa Daoud, Shada J. Alabed & Lina A. Dahabiyeh. (2021) Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies. Acta Pharmaceutica 71:2, pages 163-174.
Crossref
Crossref
Subha Sankar Paul & Goutam Biswas. (2021) Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials. Mini-Reviews in Medicinal Chemistry 21:9, pages 1123-1143.
Crossref
Crossref
N.R. Jena. (2021) Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2. Chemical Physics Impact 2, pages 100011.
Crossref
Crossref
Giuseppe Carota, Simone Ronsisvalle, Federica Panarello, Daniele Tibullo, Anna Nicolosi & Giovanni Li Volti. (2021) Role of Iron Chelation and Protease Inhibition of Natural Products on COVID-19 Infection. Journal of Clinical Medicine 10:11, pages 2306.
Crossref
Crossref
Nuran COŞKUN & Ozge ULKER. (2021) COVID-19 TEDAVİSİNDE İLAÇ-İLAÇ ETKİLEŞİMLERİNİN FARMAKOKİNETİK AÇIDAN DEĞERLENDİRİLMESİ. Ankara Universitesi Eczacilik Fakultesi Dergisi, pages 19-19.
Crossref
Crossref
Edyta Janik, Marcin Niemcewicz, Marcin Podogrocki, Joanna Saluk-Bijak & Michal Bijak. (2021) Existing Drugs Considered as Promising in COVID-19 Therapy. International Journal of Molecular Sciences 22:11, pages 5434.
Crossref
Crossref
Kien Hui Chua, Isa Naina Mohamed, Mohd Heikal Mohd Yunus, Norefrina Shafinaz Md Nor, Khidhir Kamil, Azizah Ugusman & Jaya Kumar. (2021) The Anti-Viral and Anti-Inflammatory Properties of Edible Bird’s Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application. Frontiers in Pharmacology 12.
Crossref
Crossref
Ekta Shirbhate, Preeti Patel, Vijay K Patel, Ravichandran Veerasamy, Prabodh C Sharma, Barij N Sinha & Harish Rajak. (2021) Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19. Mini-Reviews in Medicinal Chemistry 21:8, pages 1004-1016.
Crossref
Crossref
Doaa A. Ghareeb, Samar R. Saleh, Mohammed S. Nofal, Mohamed M. Y. Kaddah, Salma. F. Hassan, Inas K. Seif, Sally A. El-Zahaby, Shaimaa M. Khedr, Marwa Y. Kenawy, Aliaa A. Masoud, Salma A. Soudi, Ahmed A. Sobhy, Jaillan G. Sery, Miral G. Abd El-Wahab, Alshimaa A. Abd Elmoneam, Abdulaziz Mohsen Al-mahallawi & Maha A. El-Demellawy. (2021) Potential therapeutic and pharmacological strategies for SARS-CoV2. Journal of Pharmaceutical Investigation 51:3, pages 281-296.
Crossref
Crossref
Amir Ali Mahboobipour & Shadi Baniasadi. (2021) Clinically important drug–drug interactions in patients admitted to hospital with COVID-19: drug pairs, risk factors, and management. Drug Metabolism and Drug Interactions 36:1, pages 9-16.
Crossref
Crossref
Charlotte Kern, Verena Schöning, Carlos Chaccour & Felix Hammann. (2021) Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing. Frontiers in Pharmacology 12.
Crossref
Crossref
Omkar Indari, Shweta Jakhmola, Elangovan Manivannan & Hem Chandra Jha. (2021) An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. Frontiers in Pharmacology 12.
Crossref
Crossref
Marwan ElBagoury, Mahmoud M. Tolba, Hebatallah A. Nasser, Abdul Jabbar, Ahmed M. Elagouz, Yahia Aktham & Amy Hutchinson. (2021) The find of COVID-19 vaccine: Challenges and opportunities. Journal of Infection and Public Health 14:3, pages 389-416.
Crossref
Crossref
Bhavesh D. Kevadiya, Jatin Machhi, Jonathan Herskovitz, Maxim D. Oleynikov, Wilson R. Blomberg, Neha Bajwa, Dhruvkumar Soni, Srijanee Das, Mahmudul Hasan, Milankumar Patel, Ahmed M. Senan, Santhi Gorantla, JoEllyn McMillan, Benson Edagwa, Robert Eisenberg, Channabasavaiah B. Gurumurthy, St Patrick M. Reid, Chamindie Punyadeera, Linda Chang & Howard E. Gendelman. (2021) Pharmacotherapeutics of SARS-CoV-2 Infections. Journal of Neuroimmune Pharmacology 16:1, pages 12-37.
Crossref
Crossref
Sébastien Pasquereau, Zeina Nehme, Sandy Haidar Ahmad, Fadoua Daouad, Jeanne Van Assche, Clémentine Wallet, Christian Schwartz, Olivier Rohr, Stéphanie Morot-Bizot & Georges Herbein. (2021) Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. Viruses 13:2, pages 354.
Crossref
Crossref
Audrey Fresse, Delphine Viard, Serena Romani, Alexandre Gérard, Marion Lepelley, Fanny Rocher, Joe-Elie Salem & Milou-Daniel Drici. (2021) Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem. International Journal of Cardiology 324, pages 255-260.
Crossref
Crossref
Paola Magro, Isabella Zanella, Marta Pescarolo, Francesco Castelli & Eugenia Quiros-Roldan. (2021) Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. Biomedical Journal 44:1, pages 43-53.
Crossref
Crossref
Kavita Manchanda, Jasbir Singh, Ranjeev Bhagat, Ilmjot Kaur Tiwana & Harmanjit Singh. (2021) Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. International Journal of Risk & Safety in Medicine 32:1, pages 3-17.
Crossref
Crossref
Deepak Pradhan, Prativa Biswasroy, Amit Goyal, Goutam Ghosh & Goutam Rath. (2021) Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections. AAPS PharmSciTech 22:1.
Crossref
Crossref
Gulnara I. SyraevaS.A. MishinovaAlexey S. KolbinE.O. Eremenko. (2021) Safety profile assessment of drug products used for the pathogenetic treatment of COVID19. Clinical Microbiology and Antimicrobial Chemotherapy 23:3, pages 314-329.
Crossref
Crossref
N. A. VlasenkoYu. О. Kapustnik. (2021) FEATURES OF THE USE OF ANTIVIRAL DRUGS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY THE COVID-19 VIRAL INFECTION. Bulletin of Problems Biology and Medicine 3:1, pages 14.
Crossref
Crossref
Evellyn Claudia Wietzikoski Lovato, Lorena Neris Barboza, Samantha Wietzikoski, Amanda Nascimento Vasques de Souza, Pablo Alvarez Auth, Arquimedes Gasparotto Junior & Francislaine Aparecida dos Reis Lívero. (2021) Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Current Pharmaceutical Design 27:1, pages 115-126.
Crossref
Crossref
Pinki, Subhash & Ashu Chaudhary. (2021) Emerging Potential of Metallodrugs to Target Coronavirus:
Efficacy, Toxicity and their Mechanism of Action. Asian Journal of Chemistry 33:6, pages 1191-1207.
Crossref
Crossref
Denio A. Ridjab, Ignatius Ivan, Fanny Budiman & Dwi Jani Juliawati. (2021) Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir. Medicine 100:31, pages e26787.
Crossref
Crossref
Himani Rathi, Vishakha Burman, Sudip Kumar Datta, Satya Vati Rana, Anissa Atif Mirza, Sarama Saha, Raman Kumar & Manisha Naithani. (2021) Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2. Indian Journal of Clinical Biochemistry 36:1, pages 3-22.
Crossref
Crossref
Xueqing Wang & Yuanfang Guan. (2020) COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. Medicinal Research Reviews 41:1, pages 5-28.
Crossref
Crossref
Jung-Hyun Won & Howard Lee. (2020) The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. International Journal of Molecular Sciences 21:24, pages 9775.
Crossref
Crossref
Julia Liang, Chris Karagiannis, Eleni Pitsillou, Kevion K. Darmawan, Ken Ng, Andrew Hung & Tom C. Karagiannis. (2020) Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. Computational Biology and Chemistry 89, pages 107372.
Crossref
Crossref
Thakur Uttam Singh, Subhashree Parida, Madhu Cholenahalli Lingaraju, Manickam Kesavan, Dinesh Kumar & Raj Kumar Singh. (2020) Drug repurposing approach to fight COVID-19. Pharmacological Reports 72:6, pages 1479-1508.
Crossref
Crossref
Charu Sonkar, Dharmendra Kashyap, Nidhi Varshney, Budhadev Baral & Hem Chandra Jha. (2020) Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach. SN Comprehensive Clinical Medicine 2:12, pages 2658-2669.
Crossref
Crossref
Reena Sherin Parveen, Sherya HegdeVeena Nayak. (2020)
Investigational Drugs for the COVID 19 Pandemic – A Concise Review
. Pharmaceutical Sciences 26:Covid-19, pages S36-S48.
Crossref
Crossref
Namrta Choudhry, Xin Zhao, Dan Xu, Mark Zanin, Weisan Chen, Zifeng Yang & Jianxin Chen. (2020) Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Journal of Medicinal Chemistry 63:22, pages 13205-13227.
Crossref
Crossref
Pablo Zubiaur, Dora Koller, Miriam Saiz‐Rodríguez, Marcos Navares‐Gómez & Francisco Abad‐Santos. (2020) Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19). Clinical and Translational Science 13:6, pages 1023-1033.
Crossref
Crossref
Andrey V. Smolobochkin, Almir S. Gazizov, Nazerke K. Otegen, Julia K. Voronina, Anna G. Strelnik, Aida I. Samigullina, Alexander R. Burilov & Michail A. Pudovik. (2020) Nucleophilic Cyclization/Electrophilic Substitution of (2,2-Dialkoxyethyl)ureas: Highly Regioselective Access to Novel 4-(Het)arylimidazolidinones and Benzo[d][1,3]diazepinones. Synthesis 52:21, pages 3263-3271.
Crossref
Crossref
Mahmoud A.A. Ibrahim, Alaa H.M. Abdelrahman, Taha A. Hussien, Esraa A.A. Badr, Tarik A. Mohamed, Hesham R. El-Seedi, Paul W. Pare, Thomas Efferth & Mohamed-Elamir F. Hegazy. (2020) In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Computers in Biology and Medicine 126, pages 104046.
Crossref
Crossref
Kamran Mansouri, Mohsen Rastegari-Pouyani, Maryam Ghanbri-Movahed, Mehrnoush Safarzadeh, Sara Kiani & Zahra Ghanbari-Movahed. (2020) Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rational. Biomedicine & Pharmacotherapy 131, pages 110694.
Crossref
Crossref
Khalil Khalaf, Natalia Papp, Jadzia Tin-Tsen Chou, Doris Hana, Andrzej Mackiewicz & Mariusz Kaczmarek. (2020) SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. Frontiers in Immunology 11.
Crossref
Crossref
Thomas J. Cross, Gemma R. Takahashi, Elizabeth M. Diessner, Marquise G. Crosby, Vesta Farahmand, Shannon Zhuang, Carter T. Butts & Rachel W. Martin. (2020) Sequence Characterization and Molecular Modeling of Clinically Relevant Variants of the SARS-CoV-2 Main Protease. Biochemistry 59:39, pages 3741-3756.
Crossref
Crossref
Sophie L. Penman, Robyn T. Kiy, Rebecca L. Jensen, Christopher Beoku‐Betts, Ana Alfirevic, David Back, Saye H. Khoo, Andrew Owen, Munir Pirmohamed, B. Kevin Park, Xiaoli Meng, Christopher E. Goldring & Amy E. Chadwick. (2020) Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology 177:19, pages 4353-4374.
Crossref
Crossref
Dragana Javorac, Lazar Grahovac, Luka Manić, Nikola Stojilković, Milena Anđelković, Zorica Bulat, Danijela Đukić - Ćosić, Marijana Curcic & Aleksandra Buha Djordjevic. (2020) An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. Food and Chemical Toxicology 144, pages 111639.
Crossref
Crossref
Sally El Kantar, Bilal Nehmeh, Philippe Saad, Gabie Mitri, Celine Estephan, Mohamad Mroueh, Elias Akoury & Robin I. Taleb. (2020) Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. Drug Discovery Today 25:10, pages 1822-1838.
Crossref
Crossref
Ji Sun, Xuanyu Deng, Xiaoping Chen, Juanjuan Huang, Siqiong Huang, Yanfei Li, Jinhui Feng, Jiyang Liu & Gefei He. (2020) Incidence of Adverse Drug Reactions in COVID‐19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clinical Pharmacology & Therapeutics 108:4, pages 791-797.
Crossref
Crossref
Kenneth Lundstrom. (2020) Viral Vectors Applied for RNAi-Based Antiviral Therapy. Viruses 12:9, pages 924.
Crossref
Crossref
Mukarram Jamat Ali, Muhammad Hanif, Muhammad Adnan Haider, Muhammad Umer Ahmed, FNU Sundas, Arham Hirani, Izhan Ali Khan, Khurram Anis & Amin H. Karim. (2020) Treatment Options for COVID-19: A Review. Frontiers in Medicine 7.
Crossref
Crossref
Instiaty, I Gusti Agung Ayu Putu Sri Darmayani, Jefman Efendi Marzuki, Ferina Angelia, William, Angelina Siane, Lela Dwi Sary, Lina Yohanes, Reni Widyastuti, Riki Nova, Dewi Sharon Simorangkir, Lonah, Yolanda Safitri, Gestina Aliska & Anggi Gayatri. (2020) Antiviral treatment of COVID-19: a clinical pharmacology narrative review. Medical Journal of Indonesia 29:3, pages 332-45.
Crossref
Crossref
Amin Gasmi, Sadaf Noor, Torsak Tippairote, Maryam Dadar, Alain Menzel & Geir Bjørklund. (2020) Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clinical Immunology 215, pages 108409.
Crossref
Crossref
Maha Saber-Ayad, Mohamed A. Saleh & Eman Abu-Gharbieh. (2020) The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals 13:5, pages 96.
Crossref
Crossref
Iman Fathy Abou-El-Naga, Rasha Fadly Mady & Nermine Mogahed Fawzy Hussien Mogahed. (2020) In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum. Biomédica 40:Supl. 1, pages 89-101.
Crossref
Crossref
Kevin J. McHugh. (2020)
Employing drug delivery strategies to create safe and effective pharmaceuticals for
COVID
‐19
. Bioengineering & Translational Medicine 5:2.
Crossref
Crossref
Antonio G. Lentoor. (2020) Clinico-Immunological Status and Neurocognitive Function of Perinatally Acquired HIV-Positive Children on cART: A Cross-Sectional Correlational Study in South Africa. Frontiers in Neurology 11.
Crossref
Crossref
Monika Adamczyk-Popławska & Agnieszka Kwiatek. (2020) Covid-19 Therapy: What Have We Learned In 8 Months?. Postępy Mikrobiologii - Advancements of Microbiology 59:3, pages 207-225.
Crossref
Crossref
Peketi Rajesh Reddy, Sivanadh Musunuri, D. Ramasekhara Reddy, V. Subrahmanyam Chittala, P.V.N.S. Murthy & K. Krishnamohan. (2020) Synthesis and Characterization of Novel Analogues of Lopinavir. Asian Journal of Chemistry 33:1, pages 151-158.
Crossref
Crossref
E. Pontiki, A. Peperidou, I. Fotopoulos & D. Hadjipavlou-Litina. 2020. Cancer-Leading Proteases. Cancer-Leading Proteases
165
182
.
Umesh Panwar, Ishwar Chandra, Chandrabose Selvaraj & Sanjeev K. Singh. (2019) Current Computational Approaches for the Development of Anti-HIV Inhibitors: An Overview. Current Pharmaceutical Design 25:31, pages 3390-3405.
Crossref
Crossref
Thomas Maitre, Patrice Muret, Mathieu Blot, Anne Waldner, Michel Duong, Ali SI-Mohammed, Pascal Chavanet, Serge Aho & Lionel Piroth. (2019) Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice. Current HIV Research 17:3, pages 190-197.
Crossref
Crossref
Chandrashekhar Voshavar. (2019) Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges. Current Topics in Medicinal Chemistry 19:18, pages 1571-1598.
Crossref
Crossref
Babita Garg, Sarwar Beg, Rajendra Kumar, O.P. Katare & Bhupinder Singh. (2019) Nanostructured lipidic carriers of lopinavir for effective management of HIV-associated neurocognitive disorder. Journal of Drug Delivery Science and Technology 53, pages 101220.
Crossref
Crossref
Chandra S. Kuruva, Syam P. Gandavaram, Thaslim B. Shaik, Venkataramaiah Chintha, Naga R. Chamarthi, Sunil K. Ghosh & Rajendra Wudayagiri. (2019) Synthesis, Spectral Characterization, Docking Studies and Antiviral Activity of Phosphorylated Derivatives of Lopinavir Intermediate. ChemistrySelect 4:20, pages 6101-6105.
Crossref
Crossref
Wan‐jie Niu, Tao Sun, Li Liu, Xiao‐qian Liu, Ren‐fang Zhang, Lin Yin, Jiang‐rong Wang, Xiao‐fang Jia, Hong‐Zhou Lu, Ming‐kang Zhong, Zheng Jiao & Li‐jun Zhang. (2018) Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV. Basic & Clinical Pharmacology & Toxicology 124:4, pages 456-465.
Crossref
Crossref
Rossella Gratton, Paola Maura Tricarico, Rafael Lima Guimaraes, Fulvio Celsi & Sergio Crovella. (2018) Lopinavir/Ritonavir Treatment Induces Oxidative Stress and Caspaseindependent Apoptosis in Human Glioblastoma U-87 MG Cell Line. Current HIV Research 16:2, pages 106-112.
Crossref
Crossref
Julie A. Mennella, Phoebe S. Mathew & Elizabeth D. Lowenthal. (2017) Use of Adult Sensory Panel to Study Individual Differences in the Palatability of a Pediatric HIV Treatment Drug. Clinical Therapeutics 39:10, pages 2038-2048.
Crossref
Crossref
Vasif Ahammed, Reema Narayan, John Paul, Yogendra Nayak, Bisakha Roy, Gopal V. Shavi & Usha Y. Nayak. (2017) Development and in vivo evaluation of functionalized ritonavir proliposomes for lymphatic targeting. Life Sciences 183, pages 11-20.
Crossref
Crossref
Abhirup Mandal, Dhananjay Pal & Ashim K. Mitra. (2016) Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug. International Journal of Pharmaceutics 512:1, pages 49-60.
Crossref
Crossref
Tom De Bruyn, Bruno Stieger, Patrick F. Augustijns & Pieter P. Annaert. (2016) Clearance Prediction of HIV Protease Inhibitors in Man: Role of Hepatic Uptake. Journal of Pharmaceutical Sciences 105:2, pages 854-863.
Crossref
Crossref
Ahmed Hamed Salem, Aksana Kaefer Jones, Marilia Santini-Oliveira, Graham P. Taylor, Kristine B. Patterson, Angela M. Nilius & Cheri Enders Klein. (2016) No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects. Antimicrobial Agents and Chemotherapy 60:1, pages 400-408.
Crossref
Crossref
Charles A Veltri. (2015) Proteases: Nature’s Destroyers and the Drugs that Stop Them. Pharmacy & Pharmacology International Journal 2:6.
Crossref
Crossref
Thomas E. Kraft, Christopher Armstrong, Monique R. Heitmeier, Audrey R. Odom & Paul W. Hruz. (2015) The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir. Antimicrobial Agents and Chemotherapy 59:10, pages 6203-6209.
Crossref
Crossref
Dhruval Patel, Praveen Kumar & Hetal P. Thakkar. (2015) Lopinavir metered-dose transdermal spray through microporated skin: Permeation enhancement to achieve therapeutic needs. Journal of Drug Delivery Science and Technology 29, pages 173-180.
Crossref
Crossref
Vanja Petrovic & Micheline Piquette-Miller. (2015) Polyinosinic/Polycytidylic Acid–Mediated Changes in Maternal and Fetal Disposition of Lopinavir in Rats. Drug Metabolism and Disposition 43:7, pages 951-957.
Crossref
Crossref
Lee M Tatham, Steven P Rannard & Andrew Owen. (2015) Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. Therapeutic Delivery 6:4, pages 469-490.
Crossref
Crossref
Punna Rao Ravi, Rahul Vats, Jagadeesh Balija, Sathya Prabhu Naidu Adapa & N. Aditya. (2014) Modified pullulan nanoparticles for oral delivery of lopinavir: Formulation and pharmacokinetic evaluation. Carbohydrate Polymers 110, pages 320-328.
Crossref
Crossref
Kathleen M.S.E. Reyskens & M. Faadiel Essop. (2014) HIV protease inhibitors and onset of cardiovascular diseases: A central role for oxidative stress and dysregulation of the ubiquitin–proteasome system. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1842:2, pages 256-268.
Crossref
Crossref
Sanyog JainJagadish M Sharma, Amit K Jain & Rahul R Mahajan. (2013) Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. Nanomedicine 8:10, pages 1639-1655.
Crossref
Crossref
Sunita Gupta, Alecia G. Knight, Boriss Y. Losso, Donald K. Ingram, Jeffrey N. Keller & Annadora J. Bruce-Keller. (2012) Brain injury caused by HIV protease inhibitors: Role of lipodystrophy and insulin resistance. Antiviral Research 95:1, pages 19-29.
Crossref
Crossref
M Nikanjam, E G Chadwick, B Robbins, C Alvero, P Palumbo, R Yogev, J Pinto, R Hazra, M L Hughes, B E Heckman & E V Capparelli. (2011) Assessment of Lopinavir Pharmacokinetics With Respect to Developmental Changes in Infants and the Impact on Weight Band–Based Dosing. Clinical Pharmacology & Therapeutics 91:2, pages 243-249.
Crossref
Crossref
Christian Nsanzabana & Philip J. Rosenthal. (2011)
In Vitro
Activity of Antiretroviral Drugs against Plasmodium falciparum
. Antimicrobial Agents and Chemotherapy 55:11, pages 5073-5077.
Crossref
Crossref
Paul J. Pistell, Sunita Gupta, Alecia G. Knight, Michelle Domingue, Romina M. Uranga, Donald K. Ingram, Indu Kheterpal, Carmen Ruiz, Jeffrey N. Keller & Annadora J. Bruce-Keller. (2010) Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice. Antiviral Research 88:3, pages 334-342.
Crossref
Crossref
John Hornberger, Kit Simpson, Ashwini Shewade, Birgitta Dietz, Robert Baran & Thomas Podsadecki. (2010) Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy. Advances in Therapy 27:11, pages 763-773.
Crossref
Crossref
Catherine K. Yeung, Ping Zhao, Danny D. Shen & Kenneth E. Thummel. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
415
435
.
Zhi-wei Ye, Sandrine Camus, Patrick Augustijns & Pieter Annaert. (2010) Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharmaceutics & Drug Disposition, pages n/a-n/a.
Crossref
Crossref